Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma.

PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.


Options:
A: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation therapy | Arm Label: Radiotherapy plus Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Radiotherapy plus Bevacizumab | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Radiotherapy
B: Arm Label: radiotherapy; Type: OTHER; Interventions: Radiation: radiation therapy | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): radiotherapy
C: Arm Label: Radiotherapy (RT) alone; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: quality-of-life assessment, Radiation: radiation therapy | Arm Label: RT & Concurrent CT; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: quality-of-life assessment, Radiation: radiation therapy | Arm Label: RT + Adjuvant CT; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: adjuvant therapy, Procedure: quality-of-life assessment, Radiation: radiation therapy | Arm Label: RT & Concurrent CT + adjuvant CT; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: adjuvant therapy, Procedure: quality-of-life assessment, Radiation: radiation therapy | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): RT & Concurrent CT, RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): RT & Concurrent CT, RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT, Radiotherapy (RT) alone | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): RT & Concurrent CT, RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT, Radiotherapy (RT) alone | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): RT & Concurrent CT, RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT, Radiotherapy (RT) alone | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): RT & Concurrent CT, RT & Concurrent CT + adjuvant CT, RT + Adjuvant CT, Radiotherapy (RT) alone
D: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care

Answer: C